Biogen’s Plegridy (peginterferon beta-1a, IM) Receives EC’s Approval for Relapsing-Remitting MS

December 22, 2020 Auto Bot Biogen, European Commission, Marketing Authorization, receives, regulatory 0

Shots:

  • The approval is based on data assessing bioequivalence and AEs associated with IM administration vs SC administration of Plegridy in healthy volunteers
  • Result: The data showed that participants receiving therapy through IM experienced fewer injection site reactions (14.4 vs 32.1 %), safety profiles were similar. The frequency of injection site reactions and AEs were comparable in participants who were dosed with IM followed by SC, compared to SC followed by IM
  • The approval expands the offerings to the individuals with RMS, providing treatment option combining safety & efficacy to optimize the treatment experience with a reduction in injection site reactions

Click here ­to­ read full press release/ article | Ref: Biogen  | Image: The New York Times

The post Biogen’s Plegridy (peginterferon beta-1a, IM) Receives EC’s Approval for Relapsing-Remitting MS first appeared on PharmaShots.